| Source | Code | Name | Case count | Share of cases (%) |
|---|---|---|---|---|
| OUTPAT | OUTPAT_ICD10(L400) | Psoriasis vulgaris | 4960 | |
| PRIM_OUT | PRIM_OUT_NOT_USED_ICD10(L400) | Psoriasis vulgaris. Not used in endpoint definition. POSSIBLY INACCURATE IN COMPLEX ENDPOINTS! | 1474 | |
| INPAT | INPAT_ICD10(L400) | Psoriasis vulgaris | 889 | |
| INPAT | INPAT_ICD9(6961A) | Psoriasis and similar disorders, Other psoriasis | 301 | |
| REIMB | REIMB_KELA(319)_ICD10(L400) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Psoriasis vulgaris | 250 | |
| REIMB | REIMB_KELA(134)_ICD10(L400) | General erythroderma, Psoriasis vulgaris | 148 | |
| REIMB | REIMB_KELA(377)_ICD10(L400) | Apremilast and dimethyl fumarate (psoriasis), Psoriasis vulgaris | 21 | |
| REIMB | REIMB_KELA(281)_ICD10(L400) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Psoriasis vulgaris | 8 | |
| REIMB | REIMB_KELA(313)_ICD10(L400) | Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Psoriasis vulgaris | 7 |